QM114 for Convenience

Galderma is entering phase 3 research with its proprietary strain of clostridium botulinum bacteria, packaged for convenience in a prefilled syringe formulation.

This is part 4 of a 4-part series

Part 1: The Cosmetic Toxin Pipeline

Part 2: DAXI for Duration

Part 3: BoNTE Benefits

QM1114, developed specifically for the aesthetic market, differs mechanistically from other toxins in that it features Galderma’s proprietary strain of clostridium botulinum bacteria and is manufactured using an animal origin-free process, according to a Galderma press release.

Galderma announced positive phase 2 results for QM114 last October and is going into phase 3 research.

The selling point for this potential newcomer is that providers do not have to reconstitute it with saline and calculate their units. It’ll come ready to go.

“… this is interesting because all the current products come as a dry powder that needs to be diluted with normal saline,” Dr. Hausauer says. “Eliminating this extra step makes clinics run more efficiently and standardizes dosing. There is no room for error in mixing incorrectly. On the flip side, some providers prefer to use different dilutions in different areas based on desired outcomes (i.e., want increased spread). This would limit that flexibility and control.”

Dr. Yoelin agrees that while some would view having prefilled syringes as convenient, seasoned injectors may choose to reconstitute on their own.

“I’m very comfortable reconstituting these products,” she says.

Karen Soika, M.D., a cosmetic surgeon and owner of the aesthetic training company called The Aesthetic Masters, says reconstitution isn’t an issue for her.

“… if the cost [of QM1114] is higher, it may not be worth it if this is its only advantage,” Dr. Soika writes in an email to the Aesthetic Authority.

Disclosures: Dr. Shamban is an investigator for Revance, Allergan, Merz and Galderma. Dr. Kaufman is a principal investigator for Revance, Galderma and Allergan. Dr. Hausauer was a sub-investigator on Revance’s SAKURA 3 trial. Dr. Yoelin is an investigator for Revance and Allergan. Drs. Soika and Chaboki report no conflicts.